Dr. Deaglan J. McHugh, MD

Dr. McHugh practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.

Dr. McHugh's NPI, 1134678451, was assigned on September 27, 2016. Dr. McHugh graduated from University of Dublin Trinity College in 2009. Dr. McHugh holds New York license P03030.

Dr. McHugh's primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.

Dr. McHugh's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. Dr. McHugh is also affiliated with Stony Brook University Hospital. The medical group on file is Memorial Sloan Kettering Cancer Center. Dmand AI also links Dr. McHugh to 4 more medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. McHugh practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. McHugh's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. McHugh's licenses on file in 2 states: New York and Florida.

Dmand AI lists breast cancer, chronic leukemia, lung cancer and prostate cancer among the conditions Dr. McHugh treats.

CMS data shows 860 Medicare services from Dr. McHugh across 5 procedure codes in 2024, all of them office visits, for 314 Medicare patients. Medicare paid $71,182 for them. Every service was in an office.

CMS counts 314 Medicare patients who saw Dr. McHugh in 2024. The largest group is 75 to 84, with 147 patients. 75% of them have cancer, and 75% have high blood pressure. 7% are also on Medicaid. Their average risk score is 2.23, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. McHugh's median patient age at 75, with 4% women.

In 2024, Dr. McHugh wrote 1,553 Medicare Part D claims for 181 patients. 82% of them were for generic drugs. CMS names the drug for 1,399 of them, across 16 drugs with 11 or more claims each, at $4,300,475 in total drug cost. In 2023, CMS named 1,308 claims across 17 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 78 out of 100 for Dr. McHugh for performance year 2024, reported as part of a group. Dr. McHugh accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. McHugh as offering telehealth.

Dmand AI links 26 papers to Dr. McHugh, published from 2018 to 2025. 2025 was the busiest year, with 5. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Cisplatin and Testicular Neoplasms. Dr. McHugh has published most often in J Clin Oncol. Dr. McHugh's most frequent co-authors are Darren Richard Feldman, MD, Robert J. Motzer, MD and Samuel A. Funt, MD.

Dmand AI links Dr. McHugh to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Prostatic Neoplasms and Prostatic Diseases.

CMS Open Payments shows 4 general payments to Dr. McHugh from 2 drug and device companies from 2019 to 2025. Consulting fees make up the largest share, 56% of the total. Janssen Pharmaceuticals, Inc paid the most, $1,263.

Dr. McHugh graduated from University of Dublin Trinity College in 2009.

Dr. McHugh is in network with 10 carriers, including Aetna, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.